文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

全球多国孕妇对孕期RSV免疫接种的接受度与偏好:一项横断面研究

Acceptability and preferences regarding RSV immunisation during pregnancy: a cross-sectional study in diverse global settings.
PubMed 文献 · Vaccine · 2026-06-07

该研究在2024年3月至2025年3月期间,通过便利抽样在八个国家招募孕妇,评估其对孕期RSV疫苗接种的接受度及对母婴两种免疫策略的偏好。887名参与者中76.1%接受孕期接种,69.8%首选孕期接种而非婴儿单克隆抗体;研究强调需针对性沟通安全性与有效性关切。

要点

  • 76.1%的孕妇接受孕期RSV疫苗接种,10.8%已接种、65.3%愿意接种。
  • 69.8%偏好孕期接种,14.5%偏好婴儿单克隆抗体。
  • 既往孕期接种其他推荐疫苗与接受度及偏好正相关。

核心结论

  • 跨国研究显示孕妇对孕期RSV疫苗接种接受度高,且多数偏好该策略而非婴儿免疫。

研究设计与样本

  • 横断面研究,2024年3月至2025年3月在八个国家通过便利抽样招募孕妇,共887人。

主要发现

  • 675人(76.1%)接受孕期RSV接种,其中96人(10.8%)已接种、579人(65.3%)愿意接种。
  • 接受度在不同研究站点间从瑞士的70.4%到哥伦比亚的79.1%不等。
  • 619人(69.8%)偏好孕期接种,129人(14.5%)偏好婴儿单克隆抗体。
  • 与接种意愿独立相关的因素包括:有新生儿重症监护住院史的孩子、孕期接种其他推荐疫苗、感知卫生当局的积极影响。
  • 与偏好孕期接种独立相关的因素包括:孕期接种其他推荐疫苗;而子痫前期病史或感知疫苗相关胎儿/产科风险则倾向于偏好单克隆抗体。

临床怎么用

  • 应针对孕妇对安全性和有效性的关切进行个体化沟通,以支持孕期RSV疫苗接种决策。
  • 政策制定可考虑与家长疫苗接种偏好对齐,以促进有效实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) is the leading cause of severe lower respiratory tract infections in infants. Two effective preventive strategies exist: maternal RSV Prefusion F vaccination during pregnancy and child immunisation with monoclonal antibodies. OBJECTIVES: To assess pregnant individuals' acceptance of, and preferences between, maternal RSV vaccination and infant monoclonal antibodies across diverse global settings after receiving standardized information on RSV risks and expected protective benefits. STUDY DESIGN: Cross-sectional study conducted between March 2024 and March 2025 among pregnant individuals recruited by convenience sampling in partner centres across eight countries (Brazil, Canada, Colombia, Spain, France, Italy, Luxembourg, and Switzerland). The primary outcome was acceptance of RSV vaccination during pregnancy, and the secondary outcome was preference between maternal RSV vaccination and infant Nirsevimab; associated factors were assessed using multivariable logistic regression, with country group included as a design-related adjustment variable. RESULTS: Among 887 participants, 675 (76.1%) reported accepting RSV vaccination during pregnancy: 96 (10.8%) were already vaccinated and 579 (65.3%) would have liked to receive it when available. Acceptance of the RSV vaccine during pregnancy differed across main study sites, ranging from 70.4% in Switzerland to 79.1% in Colombia. Factors independently associated with willingness to be vaccinated included having a child previously hospitalised in neonatal intensive care unit, uptake of other recommended vaccines during pregnancy, and perceiving a positive influence from health authorities. Most of participants (69.8%, 619/887) preferred maternal RSV vaccination over child immunisation with monoclonal antibody administration (14.5%, 129/887). Factors independently associated with vaccination preference included: having received other recommended vaccines during pregnancy, whereas history of pre-eclampsia or perception of foetal or obstetrical risk associated with this vaccine favoured preference for the monoclonal antibody. Additional motivations for preferring maternal RSV vaccination included: avoiding an extra injection for the newborn, perceived greater efficacy, and a preference for endogenous antibody-mediated protection. CONCLUSION: This multinational study demonstrates high acceptance of maternal RSV vaccination and a predominant preference for this strategy over infant immunisation. These findings highlight the importance of tailored communication addressing pregnant individuals' concerns about safety and efficacy, alongside policies that align with parental vaccination preferences to facilitate effective implementation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Favre G, Pfund A, Gerbier E, et al. Acceptability and preferences regarding RSV immunisation during pregnancy: a cross-sectional study in diverse global settings. Vaccine. 2026. PMID: 42251842. doi:10.1016/j.vaccine.2026.128783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。